ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

ImmunityBio, Inc.NASDAQ: IBRX

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin growth accelerates

Q3 FY2026 selling, general & admin of $52.49M rose 59.9% year over year, ahead of the +24.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at +12.7% a year.

Context

  • Selling, general & admin amounted to 129.9% of revenue in FY2025, down 1014.8 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $31.89B (+21570.4%) for the fiscal year ending Dec 2026, a step up from the -12.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$52.49M+3.7% QoQ
Last fiscal yearDec 2025
$147.18M-12.8% YoY
LTMSep 2026
$185.41M+24.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.9%+23706.8%+23646.9 pp
1 year-12.8%+21570.4%+21583.2 pp
3-year CAGR+12.7%+860.5%+847.8 pp
5-year CAGR+386.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
147.18M USD
Year-over-year change
-12.8%
4-year CAGR
+2.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +24.0% is the 2nd highest of 10, against a peer median of -3.4%.
  • Selling, general & admin amounts to 101.6% of revenue for IBRX, versus a peer median of 39.8%.
IBRX Competitors
Selling, General & Admin for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$979M USD-7.7%-3.5%38.8%
BNTXBioNTech SELTM Jun 2026€788.8M EUR+45.9%+8.9%29.8%
LEGNLegend Biotech CorporationLTM Sep 2026$357.49M USD+10.5%+25.2%26.3%
IBRXImmunityBio, Inc.LTM Sep 2026$185.41M USD+24.0%+12.7%101.6%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$153.2M USD-3.3%+13.5%40.4%
IMCRImmunocore Holdings plcLTM Mar 2026$151.41M USD-3.4%—39.2%
VIRVir Biotechnology, Inc.LTM Mar 2026$69.19M USD——105.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M USD-11.2%-10.5%—
IMTXImmatics N.V.LTM Mar 2026€53.63M EUR+14.4%+12.3%143.8%
NKTXNkarta, Inc.LTM Mar 2026$25.06M USD-19.7%+4.0%—
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$17.8M USD-55.8%-27.2%76.9%
Peer median (excluding IBRX) —-3.4%+6.4%39.8%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.